Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Famitinib, and Nab-Paclitaxel in Advanced Solid Tumors
NCT05214976Phase 2Unknown
- Sponsor
- Hengrui
- Start
- Aug 2022
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in solid tumor (advanced stage), sponsored by Hengrui. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05214976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05214976.